Abstract:OBJECTIVE:To investigate the dynamic quantitative changes in expression of hepatitis B virus (HBV) surface antigen (HBsAg) that occurs during the natural recovery course and the short-term antivirus treatment period of patients suffering from flares in chronic hepatitis B (CHB).METHODS:CHB patients presenting for treatment of flare-ups were randomly assigned to receive treatment with Entecavir antiviral (group A, n = 39) or to naturally resolve the acute condition (group B, n = 22). All patients MELD scores were calculated and HBsAg levels and HBV DNA loads were measured upon admission (baseline), at worst-condition stage, and end of treatment/flare-up (discharge). Pairwise comparisons of intergroup differences were made to evaluate the change in the three disease parameters over time in response to the management approach.RESULTS:The levels of HBsAg were not significantly different between the two groups at baseline, worst-condition stage and discharge (group A: (3.68+/-0.45), (3.84+/-0.19) and (3.69+/-0.58) log10 cut-off index (COI) respectively; group B: (3.59+/-0.54), (3.47+/-0.76) and (3.43+/-0.68) log10 COI respectively; all P more than 0.05). However, the HBV DNA loads were significantly lower in group A than in group B at the worst-condition stage and at discharge (all P less than 0.05). In group A, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant. Also in group A, the HBV DNA load showed a gradually decreasing trend over time (baseline more than worst-condition stage more than discharge, all P less than 0.05). No significant differences were observed over time in the HBsAg levels of group A. In group B, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant (P = 0.619). Also in group B, the HBV DNA loads were significantly higher at baseline and worst-condition stage than at discharge (P = 0.000 and P = 0.003 respectively), but the difference between baseline and worst-condition stage was not significant. Finally, no significant differences were observed over time in the HBsAg levels of group B.CONCLUSION:Natural recovery from an acute flare-up of CHB is not accompanied by a change in HBsAg levels. In addition, short-term antiviral treatment to resolve the flare-up has no influence on HBsAg level.

[Transfusion of Activated Immune Cells Induced Fluctuations of HCV Titer Without Mutations in Hepatitis C Virus Core and E2 Region CTL Epitopes].

Transfusion of Activated Immune Ce Lls Induced the Transient Variatio N of HCV Quasispecies Distribution

Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8(+) T Cells Within Donor Grafts: Its Associations with Cytomegalovirus Reactivation Following Unmanipulated Allogeneic Hematopoietic Stem Cell Transplantation.

[Dynamic Change of Hepatitis B Surface Antigen Expression in Chronic Hepatitis B Patients During the Natural Recovery Course and the Short-Term Antivirus Treatment].

Thirteen to Twenty-Seven-Year Follow-Up of Patients with Hepatitis C While Transfusing or Donating Plasma

High Frequencies of Hgv and Ttv Infections in Blood Donors in Hangzhou

Variant Analysis and Immunogenicity Prediction of Envelope Gene of HCV Strains from China

Changes of the peripheral Thelper cell cytokines of patients with chronic hepatitis B during antiviral treatment

Sequence Evolution of Putative Cytotoxic T Cell Epitopes in NS3 Region of Hepatitis C Virus

Effectiveness of HCV Core Antigen and RNA Quantification in HCV-infected and HCV/HIV-1-coinfected Patients.

The Frequency and Skewed T-Cell Receptor Beta-Chain Variable Patterns of Peripheral Cd4(+)Cd25(+) Regulatory T-Cells Are Associated with Hepatitis B E Antigen Seroconversion of Chronic Hepatitis B Patients During Antiviral Treatment

[Clinical Outcomes of 283 Patients of Transfusion-Related Hepatitis C in the Northern Areas of China].

A Higher Correlation Of Hcv Core Antigen With Cd4+T Cell Counts Compared With Hcv Rna In Hcv/Hiv-1 Coinfected Patients

Novel Host Genetic Variations Associated with Spontaneous Clearance of A Single-Source Outbreak of Hcv1b Infections

Quasispecies of Hepatitis C Virus and Genetic Drift of the Hypervariable Region in Chronic Type C Hepatitis

Distinct T‐cell receptor profiles associated with hepatitis B e antigen seroconversion during entecavir treatment

Characteristics of HCV Co-Infection among HIV Infected Individuals from an Area with High Risk of Blood-Borne Infections in Central China

Variation of Hypervariable Regions of the Genome of Hepatitis C Virus in EBV Transforming PBMC from Patients with Hepatitis C

Superinfection by homotypic virus in hepatitis C virus carriers: studies on patients with post-transfusion hepatitis.

CHANGES OF ANTIBODIES AGAINST ANTIGENS ENCODED BY DIFFERENT REGIONS OF HCV GENOME IN CHRONIC HEPATITIS C PATIENTS TREATED WITH INTERFERON

Hepatitis E virus seroprevalence and molecular study among blood donors in China.